About

The Triple Helix Group is a collaboration between healthcare, academia and industry in the north-east of Scotland. The Innovation Hub chairs the weekly Triple Helix Group (THG) meeting. The aim of this group is to create the cross-system conditions that facilitate high quality innovation activity focused on key strategic challenges. The THG consists of senior members of staff from NHS Grampian, UoA, RGU, Opportunity North East and the Scottish Government. We have particularly strong relationships with the Health Services Research Unit and the Aberdeen Centre for Health Data Science.

 

Membership

Our primary role is to provide strategic and operational leadership across NHS Grampian for innovation activity.

We are most concerned with innovation activity focused on the development of ideas, testing prototypes, and evaluating products in real life clinical environments.

Our role usually doesn’t involve procuring products or implementing new devices as part of business as usual.

In almost all cases, our projects and programmes relate directly to significant healthcare delivery challenges, usually aligned with national or local strategic priorities.

Major areas of activity include medical technology devices and data science.

A key aspect of our role is to bring together consortia consisting of NHS staff, industry and academia to secure external funding to generate and test solutions to healthcare challenges.

Our partners

  • Scottish Health and Industry Partnership Group

The Scottish Health and Industry Partnership Group (SHIP) is an initiative hosted by the Chief Scientist Office (CSO) of the Chief Medical Officer Directorate and the Enterprise and Innovation Division of the Economic Development Directorate. It is aimed towards strengthening Scotland’s innovation activities in health and social care in order to solve real problems and improve quality, efficiency and sustainability of healthcare.

Find out more about the Scottish Health and Industry Partnership Group

  • Scottish Health Innovations Ltd

Scottish Health Innovations Ltd (SHIL) work in partnership with NHS Scotland to identify, protect, develop and commercialise healthcare innovations to improve patient care. Formed in 2002, SHIL is a private company registered in Scotland (SC236303) and limited by guarantee with three shareholders – Scottish Minister’s through the Chief Scientist OfficeNHS Tayside and the Golden Jubilee National Hospital.

Find out more about Scottish Health Innovations Ltd

  • Health Innovation Assessment Portal

The Health Innovation Assessment Portal (HIAP-Scotland) was designed to encourage prospective providers of new and/or innovative products and solutions to put them forward. This will allow NHS Scotland to assess how the solution might support NHS Scotland’s strategic aims, and what the associated costs and benefits would be. This initiative forms part of the response to the Scottish Government’s ‘Statement of Intent for Health and Wealth’

Find out more about the Health Innovation Assessment Portal

Opportunity North East (ONE) is the private sector leader and catalyst for economic diversification and growth in north east Scotland, developing and delivering transformational projects in the region’s key sectors. Through ONE, the private sector shapes the region’s low-carbon economy, maximises business growth opportunities and creates high-skill, high-value jobs.

In life sciences, ONE develops, funds and delivers dedicated business growth, leadership and innovation programmes, working with partners including the University of Aberdeen, Robert Gordon University and NHS Grampian. These include a pre-commercialisation programme, the ONE Life Sciences Accelerator, the ONE Life Sciences Network and the ONE Life Sciences Leadership Forum.

The University of Aberdeen’s internationally recognised disciplinary strengths in translational medicine, applied health sciences and economics, nutrition and psychology research provide the foundation for our close partnership working with NHS-Grampian on our shared Foresterhill Healthcare Campus.

The University’s Aberdeen 2040 strategy places challenge-led interdisciplinary research at the heart of our engagement with external stakeholders, including the NHS. The University’s commitment to knowledge exchange and innovation drives a clear impact strategy set in the context of our healthcare environment; across a range of examples, interdisciplinary research is successfully addressing a range of major health challenges, for example spinal fusion surgery, prostate cancer and the development of Field Cycling Imaging, a next-generation medical imaging technology. Our Trusted Research Environment, the Data Safe Haven, is the catalyst for partnership working with NHS colleagues on the application and assessment of artificial intelligence approaches to clinical radiology.

The University of Aberdeen is a committed Triple Helix partner, working closely with NHS-Grampian, Robert Gordon University and Opportunity Northeast to identify innovation opportunities focused on challenges identified in everyday clinical practice, and then to catalyse the research-and industry-led solutions that ultimately transform healthcare.

Robert Gordon University (RGU) is an innovative, inclusive, professionally focused University that has a positive impact on those we serve. Our mission is to transform people and communities by providing excellent teaching, research and enterprise opportunities to contribute to economic, social and cultural development and environmental sustainability.

RGU is undertaking high quality, internationally-recognised research that is relevant and responsive to real-world challenges; delivers significant social, cultural and economic value; and makes a contribution to sustainable economic growth, improved service provision, and increased innovation.  Through the objectives of our recently launched Research Strategy, we will develop a vibrant, collaborative and inclusive research environment that can deliver high quality outputs and public value in order to continue to strengthen our overall reputation and profile for excellence.

Our strategy in relation to research is to grow the quality and impact of our globally recognised, innovative and interdisciplinary research. We see our involvement in the Triple Helix group as one of the ways that we will do this by collaborating with public, private and third sector organisations through knowledge exchange to develop partnerships that create societal benefit.

This also supports our aim to contribute significantly towards Scotland’s economic and social regeneration: stimulating economic development by supporting organisations to be more successful, driving community interaction and engagement and fostering a vibrant culture of enterprise among our students and staff.

High Level Action Plan

With planning and co-ordination, it is expected that the high-level actions detailed below will enable the Triple Helix Group to realise the agreed vision for innovation activity in the North East.

There are myriad assets that we can exploit to fulfil our aspirations. Many are detailed in the joint NHS Grampian, RGU and UoA document “Our Commitment to Research 2019-2023, which can be found in our Board papers. The £40M transformational life sciences project: Bio therapeutic Hub for Innovation is also highlighted.

More recently, we have attracted state-of-art architecture to develop and test AI diagnostics (ICAIRD) and become partners in the national Medical Device Manufacturing Centre. We are also now collaborating with the DHI, NHS Lothian and NHS GG&C in the Health Data Exchange, a platform to co-design person-centred digital health and social care solutions. Moreover, there is substantial excitement in the development of ODIN, a proof-of-concept resource, bringing together myriad sources of live and retrospective structured and unstructured data sets creating a data loch of over 8.1 million clinical documents.

Read the action plan: Triple Helix Group High Level Action Plan June 2021.

Objectives

  • Facilitate quarterly meetings between academia and the NHS to discuss examples of key strategic challenges.
  • Facilitate six-monthly meetings between industry and the NHS to discuss examples of key strategic challenges.
  • Facilitate at least one academia, industry, and NHS event.
  • Pump prime using cross-system resources at least 3 innovation projects.
  • Applied for at least 5 grants under £100,000 or secured externals funds of this value.
  • Applied for at least 2 grants over £100,000 or secured external funds of this value.
  • Initiated at least 4 feasibility level innovation projects between academia and the NHS.
  • Initiated at least 2 feasibility level innovation projects between industry and the NHS
  • Initiated at least 1 feasibility level innovation project between academia, industry, and the NHS
  • Identify and address key cross-system impediments to agile innovation activity.

The University of Aberdeen is a charity registered in Scotland, No.SC013683